Green Tea for Cancer Risk Reduction

Research suggests that green tea and its polyphenols, particularly EGCG, have been examined in the context of cancer risk reduction, with two reviews from 2008 and 2009 indicating that the available literature supports a potential role for green tea compounds in reducing prostate cancer risk, though both reviews emphasized that further research is needed to clarify biological mechanisms and that potential toxicities should be considered. Studies indicate, however, that the broader evidence base linked here is largely composed of neutral or tangentially related research — covering topics such as fat metabolism, viral biology, and neurodegenerative disease — rather than direct investigations of green tea and cancer outcomes, which limits the strength of any overall conclusion that can be drawn from this particular set of sources. A 2023 methodological study raises an important caution applicable to all nutritional research in this area, noting that variability in the chemical composition of plant foods like those containing green tea compounds makes dietary intake estimates unreliable, and arguing that biomarker-based measurement would produce more dependable findings. A separate 2023 laboratory study found that EGCG interacted with many proteins beyond its presumed target in realistic biological environments, suggesting that observed effects in simpler experimental models may not translate straightforwardly to human biology, and underscoring that the field's understanding of how green tea compounds operate in the body remains incomplete.